Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 3—March 2021
Research Letter

Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs

Hamzah Z. Farooq1, Daniela M. Cirillo, Doris Hillemann, David Wyllie, Marieke J. van der Werf, Csaba Ködmön, and Vlad NikolayevskyyComments to Author 
Author affiliations: Public Health England, London, UK (H.Z. Farooq, D. Wyllie, V. Nikolayevskyy); San Raffaele Scientific Institute, Milan, Italy (D.M. Cirillo); Research Centre for Mycobacteria, Borstel, Germany (D. Hillemann); European Centre for Disease Prevention and Control, Stockholm, Sweden (M.J. van der Werf, C. Ködmön)

Main Article

Figure

European Union laboratories performing phenotypic DST of new tuberculosis drugs, 2019. Map courtesy of Mapbox OpenStreet Map (https://www.mapbox.com). DST, drug susceptibility testing.

Figure. European Union laboratories performing phenotypic DST of new tuberculosis drugs, 2019. Map courtesy of Mapbox OpenStreet Map (https://www.mapbox.com). DST, drug susceptibility testing.

Main Article

1Current affiliation: University of Manchester, Manchester, UK.

Page created: December 01, 2020
Page updated: February 17, 2021
Page reviewed: February 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external